Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

MK-1084 Yields Responses With Manageable Safety in KRAS G12C+ CRC

May 31st 2025

MK-1084 produced responses and was safe in KRAS G12C–mutated advanced colorectal cancer.

Sotorasib/Panitumumab Resistance May Be Linked to Genomic Alterations in KRAS G12C+ mCRC

May 31st 2025

Treatment resistance to sotorasib plus panitumumab may stem from genomic alterations in KRAS G12C–mutated CRC.

Nivolumab Plus Ipilimumab Shows Sustained PFS Benefit in MSI-H/dMMR mCRC

May 31st 2025

Nivolumab plus ipilimumab displayed superior PFS and PFS2 data vs chemotherapy and nivolumab monotherapy in mismatch repair-deficient colorectal cancer.

Frontline Anlotinib Plus CapeOX Elicits Similar Efficacy to SOC Therapy in RAS/BRAF Wild-Type mCRC

May 31st 2025

Anlotinib/chemotherapy demonstrated similar responses and PFS outcomes vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type mCRC.

ctDNA-Guided Chemo Does Not Yield RFS Benefit in Stage III Colon Cancer

May 31st 2025

Adjuvant chemotherapy decisions based on ctDNA status did not improve recurrence-free survival in stage III colon cancer.

Dr Strickler on the Efficacy of Sotorasib Plus Panitumumab/Chemo in KRAS G12C+ mCRC

May 30th 2025

John H. Strickler, MD, discusses the preliminary efficacy of sotorasib in combination with multiple agents across tumor types harboring KRAS G12C mutations.

Revisit Every OncLive On Air Episode From May 2025

May 30th 2025

Read a recap of the episodes of OncLive On Air that debuted in May 2025.

Encorafenib/Cetuximab Plus Chemo Boosts PFS in BRAF V600E+ mCRC

May 30th 2025

Encorafenib plus cetuximab and mFOLFOX6 improved progression-free survival in BRAF V600E–mutated metastatic colorectal cancer.

Dr Haldar on the Future Directions for Evaluating NeoAg-VAX in Colorectal Cancer

May 27th 2025

S. Daniel Haldar, MD, explains the future directions for evaluating NeoAg-VAX in colorectal and pancreatic cancer.

OncLive Polls Reveal Picks for Top Gastrointestinal Cancer Abstracts at ASCO 2025

May 23rd 2025

GI cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Acoustic Cluster Therapy Platform Boosts Tumor Shrinkage in Metastatic CRC

May 20th 2025

The ACTIVATE trial confirmed the safety and enhanced efficacy of Acoustic Cluster Therapy plus chemotherapy in patients with metastatic colorectal cancer.

ctDNA Aids in Elucidating the Role of Select Therapies for CRC

May 20th 2025

In the colorectal cancer space, the role of ctDNA can help reduce the use of certain therapies.

Cetuximab β Plus FOLFIRI Displays Significant Clinical Activity in First-Line mCRC

May 20th 2025

Cetuximab β was effective and safe in patients with RAS/BRAF wild-type metastatic colorectal cancer.

Capecitabine/Bevacizumab Yields Antitumor Activity and a Favorable Safety Profile in Older mCRC Population

May 13th 2025

Capecitabine/bevacizumab had favorable efficacy and safety profiles among older patients with metastatic colorectal cancer.

CX-2051 Demonstrates Preliminary Activity in Heavily Pretreated Advanced Colorectal Cancer

May 13th 2025

CX-2051 elicited an overall response rate of 28% with manageable safety in heavily pretreated colorectal cancer.

Five Under 5: Top Oncology Videos for the Week of 5/4

May 11th 2025

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors

May 9th 2025

Neoadjuvant dostarlimab led to an 82% clinical complete response and a 92% 2-year RFS rate, supporting nonoperative management in early-stage dMMR tumors.

Dr Morris on the Clinical Benefit With Nivolumab Plus Ipilimumab Across dMMR/MSI-H mCRC Subgroups

May 6th 2025

Van Karlyle Morris, MD, discusses the efficacy of nivolumab plus ipilimumab according to stratification factors in dMMR/MSI-H mCRC.

Five Under 5: Top Oncology Videos for the Week of 4/27

May 4th 2025

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

Dr André on the Safety Profile of Nivolumab/Ipilimumab in MSI-H/dMMR Metastatic CRC

May 1st 2025

Thierry André, MD, discusses the safety profile of nivolumab/ipilimumab for the treatment of patients with MSI-H/dMMR metastatic colorectal cancer.